The Action Is King<br />By Rev Shark<br />RealMoney.com Contributor<br />8/11/2009 8:58 AM EDT <br /><br />For after all, the best thing one can do when it's raining is to let it rain. <br />-- Henry Wadsworth Longfellow<br /><br />Although the pace of the market advance has slowed over the past week, a tremendous number of folks are looking for a market pullback. In many cases, it is more hope than analysis supporting the view, but lately even the bulls have been looking for the market to rest. <br /><br />The problem for the folks who are looking for a pullback is that the market is slowly working off some of its froth by moving sideways. Overbought markets can become less overbought by pulling back or by running in place for a while. <br /><br />Given how many folks are anxious to buy on a dip, it shouldn't be too surprising that we simply hold steady. Technically, that isn't all bad. It will lead to better charts as we consolidate and develop some bases, but they will be high-level bases and therefore carry more risk. <br /><br />The major dilemma of this market for many market players is that they just can't reconcile the market action with their views and experiences with the economy. There has been a disconnect between Wall Street and Main Street, and it makes it very hard for many market players to embrace this market even though it obviously is acting very well. <br /><br />Wall Street and Main Street often disagree, large because of the inclination of Wall Street to look ahead and focus primarily on the stream of earnings from major corporations. Main Street is looking at a wide variety of other things like unemployment and real estate, and isn't as efficient a discounting mechanism because an emotional component often comes into play with the populist view. <br /><br />Given how far and how fast this market has moved and the inclination to be skeptical about the economic recovery, it is very easy to doubt this market. The important thing is that you realize what you are fighting against. In trading, often the best approach is to not to overthink things, but rather to simply accept what is happening and try the best you can to embrace them. This market is simply not correcting much right now, and there is no arguing over that fact. Embrace that fact and you'll be better off. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: RWC +56.7% (also awarded order from the Department of Defense totaling $1.8 million for new P25 KNG Products), SDTH +18.5%, SEED +15.9%, AGM +15.0%, TXIC +14.6%, LGF +14.6%, BPI +8.6%, WAVX +7.4% (light volume), QGEN +6.9%, ARRY +5.6% (also reports positive results of its oral glucokinase activator in type 2 diabetes patients), QSFT +5.3%, MR +4.6%, KONG +4.3%, DGI +1.6%, FLR +0.7% (also upgraded to Buy at Wunderlich)... Other news: AVNR +73.5% (announces Positive Phase III Study Results for Zenvia), ANPI +23.2% (announces Cook Medical, a license holder of Angiotech's paclitaxel technology, reported CE Mark approval and limited commercial launch of the Zilver PTX Drug-Eluting Peripheral Stent in Europe), ANDS +17.6% (says ANA773 demonstrates significant antiviral response in early clinical trial in Hepatitis C patient), BEXP +17.3% (announces ~2,154 BOEPD Bakken Well; also upgraded to Overweight at Weisel), WEN +6.7% (Cramer makes positive comments on MadMoney), ONTY +5.3% (still checking), TLAB +1.7% ( to repurchase up to $200 mln in common shares)... Analyst comments: ELON +9.2% (upgraded to Neutral from Underweight at Piper Jaffray), HGSI +7.6% (target raised to $30 at Leerink Swann), KFN +3.9% (upgraded to Outperform at FBR Capital), BTU +2.0% (added to Conviction Buy List at Goldman - Reuters), ANR +1.9% (upgraded to Outperform at BMO), KR +1.7% (initiated with Buy at Deutsche), DEO +1.4% and AIXG +1.1% (upgraded to Buy at Deutsche).<br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: JAV -26.5% (also reports Ereska Phase III trial results in postoperative orthopedic pain), RINO -17.6%, BIDZ -17.5%, WH -15.4%, CHNG -13.7%, MTXX -13.1%, ZOLT -12.7% (light volume), NNI -11.6%, FRPT -11.1%, PRXL -9.7% (also downgraded to Market Perform from Outperform at Raymond James), CPST -9.1%, FEED -6.1%, CRTX -6.0%, DTSI -5.7% (also downgraded to Mkt Perform at Barrington Research), CLNE -5.0%, MDR -3.8%, NUAN -3.7%, PETD -3.7% (also announces a 3.75 mln share common stock offering), ETP -3.6% (also downgraded to Mkt Perform from Outperform at Morgan Keegan)... Select European financials ticking lower: LYG -4.8%, RBS -4.7%, HBC -1.3%, BCS -1.1%... Other news: SGEN -9.2% (announces proposed public offering of 9 mln shares of common stock), RST -7.7% (announces filing of registration statement for public offering of common stock of 4,085,000 shares), PSB -6.9% (announces 2,500,000 share proposed offering of common stock), HPT -6.6% (announces that it has commenced a 5 mln share common stock offering), SKT -5.5% (announces that it commenced a 3 mln share common stock offering), MEA -5.2% (announces sales of 6 mln shares of its common stock at $4.18 for ~$25 mln in proceeds), SPH -5.2% (announces public offering of 2.2 mln common units), AGNC -4.7% (commences public offering of 3.25 mln of common stock), BWP -4.2% (announces plans to offer 7 mln common units), BG -3.9% (commenced a 10 mln share common stock offering), S -3.5% (announces a $1.3 bln senior notes offering), FRT -2.7% (announces that it intends to raise $90 mln in equity through the issuance of new common shares of beneficial interest in an underwritten public offering pursuant to its effective shelf), RIMM -1.5% (still checking for anything specific)... Analyst comments: MBI -10.9% (downgraded to Underweight at JPMorgan), AEG -3.8% (downgraded to Neutral at Credit Suisse), DYN -3.6% (downgraded to Hold at Deutsche), YUM -2.1% (downgraded to Neutral at UBS).